Advanced

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Lindblad, O LU ; Cordero, E LU ; Puissant, A; Macaulay, L.; Ramos, A; Kabir, N N; Sun, J LU ; Vallon-Christersson, J LU ; Haraldsson, K LU and Hemann, M T, et al. (2016) In Oncogene 35(39). p.5119-5131
Abstract

Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib. Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors. Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable... (More)

Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib. Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors. Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent. Gene expression analysis of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array analysis. Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines. Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model. Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.Oncogene advance online publication, 21 March 2016; doi:10.1038/onc.2016.41.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oncogene
volume
35
issue
39
pages
13 pages
publisher
Nature Publishing Group
external identifiers
  • Scopus:84989944137
  • WOS:000384433000004
ISSN
1476-5594
DOI
10.1038/onc.2016.41
language
English
LU publication?
yes
id
165b140e-0f01-48b0-8cbd-f155e1592064
date added to LUP
2016-04-15 11:41:43
date last changed
2017-01-01 08:22:58
@article{165b140e-0f01-48b0-8cbd-f155e1592064,
  abstract     = {<p>Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib. Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors. Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent. Gene expression analysis of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array analysis. Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines. Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model. Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.Oncogene advance online publication, 21 March 2016; doi:10.1038/onc.2016.41.</p>},
  author       = {Lindblad, O and Cordero, E and Puissant, A and Macaulay, L. and Ramos, A and Kabir, N N and Sun, J and Vallon-Christersson, J and Haraldsson, K and Hemann, M T and Borg, Åke and Levander, F and Stegmaier, K and Pietras, K and Rönnstrand, L and Kazi, J U},
  issn         = {1476-5594},
  language     = {eng},
  month        = {09},
  number       = {39},
  pages        = {5119--5131},
  publisher    = {Nature Publishing Group},
  series       = {Oncogene},
  title        = {Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML},
  url          = {http://dx.doi.org/10.1038/onc.2016.41},
  volume       = {35},
  year         = {2016},
}